MTS-109

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameMTS-109
Drug Alias NameMTS-109MTS109
ClassificationCell and gene therapy > Gene therapy > mRNACell and gene therapy > Gene therapy > LNP
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMetis Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMETiS PharmaceuticalsMetis Therapeutics IncShanghai Changzheng Hospital
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A